CHEMOMAB THERAPEUTICS LTD

Chemomab Shares Plunge 53%: Low Liquidity, 200‑Day Gap Sparks Investor Worry

Chemomab Therapeutics’ shares tumble 53 % and trade far below its 200‑day average, highlighting low liquidity, steep decline and uncertain biotech prospects.

CHEMOMAB THERAPEUTICS LTD
Israel
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

Vanessa Liu

24/10/2026, 06:14

3 minutes to read

Chemomab Therapeutics Shares Drop 2.5% Amid 52‑Week Low of $1.05 – Market Snapshot

Explore Chemomab Therapeutics’ latest Nasdaq performance: 2.54% drop to $1.08, market cap $8.4 M, and a 52‑week high of $3.44—deep dive into its fibrosis‑focused biotech journey.

CHEMOMAB THERAPEUTICS LTD
Israel
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

Elliot Mercer

23/10/2026, 05:29

One minute to read